PharmAthene Company Profile (NYSE:PIP)

About PharmAthene (NYSE:PIP)

PharmAthene logoPharmathene, Inc. (Pharmathene) is a biodefense company. The Company is focused on the development of medical counter measures against biological and chemical threats. The Company is involved in the development of two next generation anthrax vaccines. The Company's anthrax vaccines use recombinant protective antigen (rPA) manufacturing processes. The Company's product portfolio includes recombinant butyrylcholinesterase (rBChE) bioscavenger, which is used in prevention and treatment of nerve agent poisoning. The Company has developed a recombinant form of human butyrylcholinesterase for pre- and post-exposure therapy to patients with nerve agent attacks. Its rBChE bioscavenger acts with mechanism, which includes reversal of the acute toxicity associated with organophosphate poisoning agents used in chemical warfare (cholinergic crisis). Its development program also includes Valortim for monoclonal human antibody treatment.

Industry, Sector and Symbol:
  • Sector: Finance
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NYSE:PIP
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $0.77
  • 200 Day Moving Avg: $2.08
  • 52 Week Range: $0.47 - $3.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.29
  • P/E Growth: 0.00
  • Average Volume: 4.43 million shs.

Frequently Asked Questions for PharmAthene (NYSE:PIP)

What is PharmAthene's stock symbol?

PharmAthene trades on the New York Stock Exchange (NYSE) under the ticker symbol "PIP."

How often does PharmAthene pay dividends? What is the dividend yield for PharmAthene?

PharmAthene announced a special dividend on Monday, November 21st. Investors of record on Sunday, January 24th will be given a dividend of $2.91 per share on Friday, February 3rd. The ex-dividend date of this dividend is Monday, February 6th. View PharmAthene's Dividend History.

How were PharmAthene's earnings last quarter?

PharmAthene, Inc. (NYSE:PIP) announced its quarterly earnings data on Monday, March, 9th. The company reported ($0.04) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.01. The firm had revenue of $1.83 million for the quarter. View PharmAthene's Earnings History.

Are investors shorting PharmAthene?

PharmAthene saw a decrease in short interest during the month of April. As of April 28th, there was short interest totalling 1,895,846 shares, a decrease of 24.8% from the April 13th total of 2,519,695 shares. Based on an average trading volume of 638,047 shares, the short-interest ratio is presently 3.0 days.

Who are some of PharmAthene's key competitors?

Who owns PharmAthene stock?

PharmAthene's stock is owned by a number of of institutional and retail investors. Top institutional investors include NOVARTIS BIOVENTURES LTD (11.10%) and TRUFFLE CAPITAL S.A.S. (10.10%). Company insiders that own PharmAthene stock include Eric I Richman and Prescott Group Capital Managem. View Institutional Ownership Trends for PharmAthene.

How do I buy PharmAthene stock?

Shares of PharmAthene can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of PharmAthene stock cost?

One share of PharmAthene stock can currently be purchased for approximately $0.65.

Analyst Ratings

Consensus Ratings for PharmAthene (NYSE:PIP) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for PharmAthene (NYSE:PIP)
No equities research coverage for this company has been tracked by


Earnings History for PharmAthene (NYSE:PIP)
Earnings by Quarter for PharmAthene (NYSE:PIP)
Earnings History by Quarter for PharmAthene (NYSE:PIP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/9/2015($0.03)($0.04)$1.83 millionViewN/AView Earnings Details
11/6/2014($0.03)($0.07)$3.50 million$0.96 millionViewN/AView Earnings Details
8/4/2014($0.06)($0.01)$3.66 millionViewN/AView Earnings Details
5/8/2014($0.06)($0.04)$3.74 millionViewN/AView Earnings Details
3/11/2014Q4($0.05)($0.08)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for PharmAthene (NYSE:PIP)
Current Year EPS Consensus Estimate: $-0.10 EPS
Next Year EPS Consensus Estimate: $-0.07 EPS


Current Dividend Information for PharmAthene (NYSE:PIP)
Most Recent Dividend:2/3/2017
Dividend Yield:0.00%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:0.00% (Based on This Year's Estimates)
0.00% (Based on Next Year's Estimates)
Dividend Payments by Quarter for PharmAthene (NYSE:PIP)

Dividend History by Quarter for PharmAthene (NYSE:PIP)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for PharmAthene (NYSE:PIP)
Insider Trades by Quarter for PharmAthene (NYSE:PIP)
Insider Trades by Quarter for PharmAthene (NYSE:PIP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/9/2016Prescott Group Capital ManagemMajor ShareholderSell1,354,632$3.26$4,416,100.32View SEC Filing  
4/13/2016Eric I RichmanDirectorSell329,354$2.20$724,578.80View SEC Filing  
4/8/2016Eric I RichmanDirectorSell11,767$2.20$25,887.40View SEC Filing  
3/19/2015Peter Steven StDirectorBuy25,000$1.65$41,250.00View SEC Filing  
1/7/2015Linda L ChangCFOSell29,600$2.10$62,160.00View SEC Filing  
9/22/2014Prescott Group Capital ManagemMajor ShareholderBuy15,000$1.55$23,250.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for PharmAthene (NYSE:PIP)
Latest Headlines for PharmAthene (NYSE:PIP)
DateHeadline logoPharmAthene, Inc. (PIP) Sees Large Decrease in Short Interest - May 10 at 7:00 AM logoToday's Research Reports on Biotech Stocks to Watch: AVEO Pharmaceuticals and PharmAthene - May 5 at 8:41 AM logoPharmAthene (PIP) Earning Positive Media Coverage, Study Shows - May 4 at 2:56 PM logoPharmAthene reports 1Q loss - May 4 at 8:15 AM logoPharmAthene Reports First Quarter 2017 Financial and Operational Results - PR Newswire (press release) - May 3 at 7:47 PM logoPharmAthene Reports First Quarter 2017 Financial and Operational Results - May 3 at 7:47 PM logoPharmAthene (PIP) Earns Daily Media Sentiment Score of 0.21 - April 30 at 5:45 PM logoPharmAthene (PIP) Given News Impact Score of 0.01 - April 27 at 6:50 PM logoPharmAthene (PIP), Altimmune Combination Approved to Trade on Nasdaq Global Under Ticker ALT (ALT) - April 26 at 11:06 PM logoPharmAthene (PIP), Altimmune Combination Approved to Trade on Nasdaq Global Under Ticker ALT (ALT) - - April 26 at 6:02 PM logoPharmAthene and Altimmune Announce Combined Company Approved for Trading on Nasdaq Global Market - April 26 at 6:02 PM logoETFs with exposure to PharmAthene, Inc. : April 19, 2017 - April 19 at 7:13 PM logoSomewhat Critical Media Coverage Somewhat Likely to Impact PharmAthene (PIP) Share Price - April 17 at 5:01 PM logoPharmAthene (PIP) Given Daily News Impact Score of -0.10 - April 14 at 1:08 PM logoPharmAthene, Inc. (PIP) Sees Large Increase in Short Interest - April 11 at 7:11 PM logoETFs with exposure to PharmAthene, Inc. : April 7, 2017 - April 7 at 7:37 PM logoPHARMATHENE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - March 29 at 7:58 PM logoAltimmune Receives $7.3 Million Contract Modification from BARDA to Fund Manufacturing of its First-In-Class Anthrax Vaccine Candidate NasoShield™ - March 28 at 9:44 AM logoPharmAthene, Inc. (PIP) Short Interest Update - March 25 at 7:14 AM logoPHARMATHENE, INC Financials - March 18 at 6:36 PM logoPharmAthene Reports Year-End 2016 Financial and Operational Results - March 14 at 6:44 PM logoPHARMATHENE, INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statement - March 14 at 6:44 PM logoPharmAthene Announces Record Date and Meeting Date for Special Meeting of Stockholders Regarding Proposed Merger Transaction with Altimmune - March 13 at 9:46 AM logoPharmAthene, Inc. (PIP) Short Interest Down 56.8% in February - March 9 at 6:30 PM logoPepsico CFO: We have terrific momentum - February 16 at 6:51 PM logoPepsico CFO: Great business in Mexico - February 16 at 6:51 PM logoBiotech Premarket Movers: PharmAthene, Earth Science Tech, Pulmatrix - February 7 at 9:03 PM logoAltimmune to Present at the BIO CEO & Investor Conference - February 6 at 9:06 AM logoForm 425 PHARMATHENE, INC Filed by: PHARMATHENE, INC - February 1 at 9:41 PM logo[$$] Gormley's Take: As IPO Market Tightens, Biotechs Find Another Route to Public Listing - February 1 at 9:41 PM logoPharmAthene and Altimmune to Merge in All-Stock Deal - January 23 at 7:33 PM logoTwo of region's anthrax-fighting companies announce merger - January 20 at 8:05 PM logoPharmAthene (PIP), Altimmune to Merge in All-Stock Transaction - - January 20 at 1:18 AM logoPharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases - January 20 at 1:18 AM logo6:32 am PharmAthene and privately-held Altimmune announce merger in an all-stock transaction - January 20 at 1:17 AM logoPHARMATHENE, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Off - January 20 at 1:17 AM logoMid-Afternoon Market Update: Dow Slides Over 100 Points; CSX Shares Spike Higher - January 19 at 4:05 PM



PharmAthene (PIP) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by Staff